Stages By Mayo Clinic Staff Staging is a way to describe how serious transthyretin amyloid cardiomyopathy (ATTR-CM) is. Staging also helps your healthcare team know your outlook, also called prognosis. But it doesn't tell you exactly what will happen. It also doesn't say how much amyloid is in your heart or other parts of your body. Staging can help your healthcare team plan the right treatment for you. There are two commonly used systems to help stage ATTR cardiac amyloidosis. The Mayo Clinic staging system uses the results from NT-proBNP and troponin blood tests. The tests show if there are signs of stress or damage to the heart. This system was developed for wild-type ATTR cardiac amyloidosis. It groups the condition from stage 1 to stage 3. Stage 1 means earlier disease. Stage 3 means more serious disease. The National Amyloidosis Centre staging system uses NT-proBNP and a measure of kidney function called estimated glomerular filtration rate (eGFR). It can be used for both wild-type and hereditary ATTR cardiac amyloidosis. It groups the condition from stage 1 to stage 3. Stage 1 means earlier disease. Stage 3 means more serious disease. An expanded version adds stage 4, but it may not be used everywhere yet. Your healthcare team can explain which staging system it uses. The stage is only one part of your care. Your symptoms and other test results matter too. How well you do with treatment also matters. Request an appointment Diagnosis & treatmentDoctors & departments Sept. 15, 2026 Share on: FacebookTwitter Show references Kittleson MM, et al. Transthyretin cardiac amyloidosis evaluation and management: 2025 ACC concise clinical guidance. Journal of the American College of Cardiology. 2026; doi:10.1016/j.jacc.2025.09.004. Arbelo E, et al. 2023 ESC Guidelines for the management of cardiomyopathies. European Heart Journal. 2023; doi:10.1093/eurheartj/ehad194. Bhatt K, et al. Hereditary transthyretin amyloidosis in patients referred to a genetic testing program. Journal of the American Heart Association. 2024; doi:10.1161/JAHA.123.033770. Layman AJ, et al. Bioepidemiology of cardiac amyloidosis. Cardiovascular Pathology. 2026; doi:10.1016/j.carpath.2026.107849. Maurer MS, et al. Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. The New England Journal of Medicine. 2018; doi:10.1056/NEJMoa1805689. Gillmore JD, et al. Efficacy and safety of acoramidis in transthyretin amyloid cardiomyopathy. The New England Journal of Medicine. 2024; doi:10.1056/NEJMoa2305434. Tersalvi G, et al. Cardiac amyloidosis: Disease overview and novel pathophysiologic insights. Journal of Nuclear Cardiology. 2026; doi:10.1016/j.nuclcard.2026.102723. Ruberg FL, et al. Cardiac amyloidosis due to transthyretin protein: A review. JAMA. 2024; doi:10.1001/jama.2024.0442. Fontana M, et al. Vutrisiran in patients with transthyretin amyloidosis with cardiomyopathy. The New England Journal of Medicine. 2025; doi:10.1056/NEJMoa2409134. Autherith M, et al. Amyloid-specific medication in transthyretin amyloid cardiomyopathy: A systematic review and meta-analysis of cardiovascular outcome trials. Journal of Cardiac Failure. 2025; doi:10.1016/j.cardfail.2025.08.002. Bloom MW, et al. Cardiac amyloidosis. Annals of Internal Medicine. 2023; doi:10.7326/AITC202303210. Del Franco A, et al. Standard therapy in cardiac amyloidosis: What is known, what is "gray." Heart Failure Clinics. 2024; doi:10.1016/j.hfc.2024.03.004. Clerc OF, et al. Radionuclide imaging of cardiac amyloidosis: An update and future aspects. Seminars in Nuclear Medicine. 2024; doi:10.1053/j.semnuclmed.2024.05.012. Bampatsias D, et al. Treatment of transthyretin cardiac amyloidosis. Current Opinion in Cardiology. 2024; doi:10.1097/HCO.0000000000001156. Kraus MJ, et al. Outcomes in patients with cardiac amyloidosis undergoing heart transplantation: The Eurotransplant experience. Journal of Heart and Lung Transplantation. 2023; doi:10.1016/j.healun.2023.01.001. Nitsche C, et al. Expansion of the National Amyloidosis Centre staging system to detect early mortality in transthyretin cardiac amyloidosis. European Journal of Heart Failure. 2024; doi:10.1002/ejhf.3354. Boretto P, et al. Prognosis prediction in cardiac amyloidosis by cardiac magnetic resonance imaging: A systematic review with meta-analysis. European Heart Journal Open. 2023; doi:10.1093/ehjopen/oead092. Transthyretin amyloid cardiomyopathy (ATTR-CM). American Heart Association. https://www.heart.org/en/health-topics/cardiomyopathy/what-is-cardiomyopathy-in-adults/transthyretin-amyloid-cardiomyopathy-attr-cm. Accessed Aug. 26, 2026. Genetic testing and counseling for hereditary transthyretin amyloidosis (hATTR). American Heart Association. https://www.heart.org/en/health-topics/cardiomyopathy/understand-your-risk-for-cardiomyopathy/genetic-testing-for-hattr-amyloidosis. Accessed Aug. 26, 2026. Libby P, et al., eds. Cardiac amyloidosis. In: Braunwald's Heart Disease: A Textbook of Cardiovascular Medicine. 13th ed. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 26, 2026. Ferri FF. Amyloidosis. In: Ferri's Clinical Advisor 2026. Elsevier; 2026. https://www.clinicalkey.com. Accessed Aug. 26, 2026. Fontana M, et al. The last decade in cardiac amyloidosis: Advances in understanding pathophysiology, diagnosis and quantification, prognosis, treatment strategies, and monitoring response. JACC: Cardiovascular Imaging. 2025; doi:10.1016/j.jcmg.2024.10.011. Amyloidosis. Merck Manual Professional Version. https://www.merckmanuals.com/professional/hematology-and-oncology/amyloidosis/amyloidosis. Accessed Aug. 26, 2026. Garcia-Pavia P, et al. Diagnosis and treatment of cardiac amyloidosis: A position statement of the ESC Working Group on Myocardial and Pericardial Diseases. European Heart Journal. 2021; doi:10.1093/eurheartj/ehab072. Dorbala S, et al. ASNC/AHA/ASE/EANM/HFSA/ISA/SCMR/SNMMI expert consensus recommendations for multimodality imaging in cardiac amyloidosis: Part 1 of 2 — Evidence base and standardized methods of imaging. Circulation: Cardiovascular Imaging. 2021; doi:10.1161/HCI.0000000000000029. Sripusanapan A, et al. Catheter ablation for atrial fibrillation in cardiac amyloidosis: A systematic review and meta-analysis. Journal of Arrhythmia. 2026; doi:10.1002/joa3.70441. Raslan MA, et al. Prognostic factors and implantable cardioverter-defibrillator outcomes in transthyretin cardiac amyloidosis: A comprehensive retrospective study. Reviews in Cardiovascular Medicine. 2026; doi:10.31083/RCM39760. Hamza I, et al. Echocardiographic phenotypic differences between light-chain and transthyretin cardiac amyloid and relation to outcome. Journal of the American Society of Echocardiography. 2025; doi:10.1016/j.echo.2025.08.017. Tersalvi G, et al. Pathology-based validation of quantitative SPECT/CT in patients with suspected transthyretin amyloid cardiomyopathy. Circulation: Cardiovascular Imaging. 2026; doi:10.1161/CIRCIMAGING.126.019832. Medical review (expert opinion). Mayo Clinic. Sept. 10, 2026. Tafamidis. Elsevier Drug Information. https://www.clinicalkey.com. Accessed Sept. 1, 2026. Acoramidis. Elsevier Drug Information. https://www.clinicalkey.com. Accessed Sept. 1, 2026. Vutrisiran. Elsevier Drug Information. https://www.clinicalkey.com. Accessed Sept. 1, 2026. Related Associated Procedures Cardiac ablation Chest X-rays Echocardiogram Electrocardiogram (ECG or EKG) Genetic testing Heart transplant Implantable cardioverter-defibrillators (ICDs) Kappa and lambda free light chain test MRI Pacemaker Show more associated procedures Transthyretin amyloid cardiomyopathy (ATTR-CM)Symptoms&causesDiagnosis&treatmentStagesDoctors&departments CON-20607272 Diseases & Conditions Transthyretin amyloid cardiomyopathy (ATTR-CM)